Screener
Corvus Pharmaceuticals CRVS Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Accounts payable | 2,206 | (1,274) |
| Accrued and other liabilities | 499 | 146 |
| Operating lease liability | (103) | 31 |
| Net cash used in operating activities | (10,374) | (8,263) |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (161,737) | (7,708) |
| Maturities of marketable securities | 16,982 | 11,987 |
| Purchases of property and equipment | (91) | (36) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's operating cash flow?
- Corvus Pharmaceuticals (CRVS) reported operating cash flow of -$10.37M in Q1 2026.
- How has Corvus Pharmaceuticals's operating cash flow changed year-over-year?
- Corvus Pharmaceuticals's operating cash flow decreased by 25.5% year-over-year, from -$8.26M to -$10.37M.
- What is the long-term trend for Corvus Pharmaceuticals's operating cash flow?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's operating cash flow has grown at a -2.8% compound annual growth rate (CAGR), from -$36.72M to -$32.8M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Corvus Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude